New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2013
08:42 EDTCCXIChemoCentryx completes target enrollment of CCX140 Phase II trial
ChemoCentryx announced that it has completed the target enrollment of 270 patients in a Phase II clinical trial in diabetic nephropathy with CCX140, an inhibitor of the chemokine receptor known as CCR2 and the Company's lead wholly owned drug candidate. Enrollment will be closed by June 30, 2013, at which time ChemoCentryx expects total enrollment to exceed 300 patients in the randomized, double-blind, placebo-controlled study.
News For CCXI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
16:31 EDTCCXIChemoCentryx grated FDA orphan-drug designation for CCX168
Subscribe for More Information
November 18, 2014
16:07 EDTCCXIChemoCentryx atypical hemolytic uremic syndrome treatment granted orphan status
Subscribe for More Information
November 17, 2014
08:52 EDTCCXIChemoCentryx reported additional data from CCX168 Phase II clinical trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use